Recent advances in B-RAF inhibitors as anticancer agents

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• The BRAF gene plays a role in cell growth and movement.
• BRAF mutations, particularly V600E, are key biomarkers in cancers like melanoma, thyroid, and colorectal cancer.
• Understanding BRAF is crucial for targeted cancer therapy.

Purpose of the Study:

• To review the structure and function of the BRAF enzyme.
• To explore BRAF's role in various cancers.
• To summarize investigational BRAF inhibitors, their chemical classification, and structure-activity relationships (SAR).

Main Methods:

• Literature review of patented and non-patented research from the last decade.
• Analysis of published data on BRAF inhibitors.
• Compilation of SAR studies for BRAF inhibitors.

Main Results:

• Overview of BRAF enzyme structure, function, and cancer-related roles.
• Identification of B-RAF V600E as a significant cancer biomarker.
• Summary of chemical classes and SAR for investigational BRAF inhibitors.

Conclusions:

• BRAF V600E mutation is a critical biomarker across multiple cancer types.
• SAR analysis provides insights into structural requirements for selective BRAF inhibition.
• This review facilitates the development of novel BRAF-targeted anticancer agents.